indirubin-5-sulfonate has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Wang, Z | 1 |
| Wei, C | 1 |
| Wang, J | 1 |
| Xu, Y | 1 |
| Bai, G | 1 |
| Yao, Q | 1 |
| Zhang, L | 1 |
| Chen, Y | 1 |
1 review available for indirubin-5-sulfonate and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship.
Topics: Antineoplastic Agents; Cell Survival; Chemistry, Pharmaceutical; Drugs, Chinese Herbal; Humans; Indo | 2021 |